Advertisement

Topics

Latest "Rosuvastatin Placebo Critically" News Stories

17:48 EDT 14th August 2018 | BioPortfolio

Here are the most relevant search results for "Rosuvastatin Placebo Critically" found in our extensive news archives from over 250 global news sources.

More Information about Rosuvastatin Placebo Critically on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Rosuvastatin Placebo Critically for you to read. Along with our medical data and news we also list Rosuvastatin Placebo Critically Clinical Trials, which are updated daily. BioPortfolio also has a large database of Rosuvastatin Placebo Critically Companies for you to search.

Showing "Rosuvastatin Placebo Critically" News Articles 1–25 of 1,100+

Tuesday 14th August 2018

MetrioPharm AG: MetrioPharm Achieves 50% of Target Patients Randomized in MP1032 Phase II Clinical Trial

EQS Group-News: MetrioPharm AG / Key word(s): Study 14.08.2018 / 15:20 Zurich, August 14, 2018. MetrioPharm AG, a pharmaceutical biotech company developing drugs for chronic inflammatory diseases, today announced that more than 50% of patients with moderate-to-severe psoriasis (PASI entry score 10-20) have been randomized in the company's ongoing Phase II clinical trial. The Phase II st...


Ironshore Pharmaceuticals Announces Agreement for $143 Million in Senior Secured Notes Financing

Ironshore Pharmaceuticals & Development, Inc. (“Ironshore”), a wholly owned subsidiary of Highland Therapeutics Inc., today announced that it has entered into agreements with purchasers to raise approximate

Entasis Therapeutics Announces Positive Topline Results from Phase 2 Trial of ETX2514SUL in Patients with Complicated Urinary Tract Infections including Acute Pyelonephritis

ETX2514SUL was generally well tolerated Phase 3 to initiate first quarter 2019 Entasis Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, reported positive topline results from the company’s multi-national Phase 2 clinical trial of it


GTx Provides Corporate Update and Reports Second Quarter 2018 Financial Results

-- Completed patient enrollment in the ASTRID Trial, a Phase 2 double-blinded, placebo-controlled clinical trial of enobosarm in Stress Urinary Incontinence -- -- Top-line results from the ASTRID Trial expected early in the fourth quarter of 2018 -- -- Updated results from Phase 2 proof-of-concept (POC) clinical trial of enobosarm ...

Caligor Coghlan Appoints Lisa Rich-Milan as Chief Executive Officer

Caligor Coghlan, a leading biopharmaceutical services company providing global clinical trial material management, supply solutions and expanded access program management, today announced the appointment of Lisa Rich-Milan as Chief Executive Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2018081...

Monday 13th August 2018

Astute Medical Inc Medical Equipment Deals and Alliances Profile [Report Updated: 11052018] Prices from USD $250

SummaryAstute Medical Inc Astute Medical is a healthcare service provider that provides diagnostic products. The company offers biomarker products such as nephro check test and astute meter. Its products are used in the field of identifying and validating biomarkers of acute kidney injury through clinically useful tools for assessing acute conditions in critically ill patients. Astute Medical's as...

An African-specific profile of pharmacogene variants for rosuvastatin plasma variability: limited role for SLCO1B1 c.521T>C and ABCG2 c.421A>C

Daylong State Fair event on Aug. 27 aims to normalize conversation about mental health

Andy Steiner Two years ago, self-described Minnesota State Fair enthusiast Dave Lee had an idea. An appointee to Minnesota Gov. Mark Dayton’s State Advisory Council on Mental Health, Lee was visiting the fair, as he does every year without fail, when he decided that the mammoth event would be the perfect place to increase public understand...

US Bioservices Selected by Alnylam Pharmaceuticals as a Specialty Pharmacy Partner for ONPATTRO™ (patisiran)

Specialty pharmacy to support bringing new FDA-approved medicine to patients US Bioservices, a specialty pharmacy that is a part of AmerisourceBergen, announced today that it has been selected by Alnylam Pharmaceuticals to be one of the specialty pharmacies to dispense ONPATTRO™ (patisiran) lipid complex injection. ONPATTRO was approved by the...

Cancer Prevention Pharmaceuticals Completes North American Licensing Deal with Mallinckrodt

License includes 50/50 profit share and additional payments of up to $185 million dependent on achieving clinical development and sales milestones, and subject to certain reductions Phase 3 clinical trial results for CPP-1X/sul in patients with familial adenomatous polyposis expected in 1H 2019 Cancer Prevention Pharmaceuticals, Inc. (CPP), a ...

Vitamin D No Benefit in Pregnancy for Fetal or Infant Growth

Supplementation in a population of pregnant women with high rates of vitamin D deficiency showed no effect on fetal or infant growth measures compared with placebo. Medscape Medical News

Sunday 12th August 2018

Impactful science

American cell biologist Randy Wayne Schekman’s fascination with microbiology started over 50 years ago with a toy microscope. Five years ago, Schekman, a Professor of molecular and cell biology at the University of California, Berkeley, received the Nobel Prize in Physiology or Medicine for the discoveries of machinery regulating vesicle traffic, a major transport system in our cells. He will ...

Samsung Bioepis to Initiate Phase 1 Clinical Trial of SB26 Ulinastatin-Fc Fusion Protein

SB26, also known as TAK-671, is intended to treat severe acute pancreatitis SB26 is the first therapeutic candidate in the risk-sharing strategic collaboration agreement between Samsung Bioepis and Takeda to co-develop multiple novel biologic therapies. Samsung Bioepis Co., Ltd. today announced it will soon begin a ...

Saturday 11th August 2018

Zhejiang Jingxin Pharmaceutical Co Ltd 002020 Financial and Strategic SWOT Analysis Review [Report Updated: 08062018] Prices from USD $300

SummaryZhejiang Jingxin Pharmaceutical Co Ltd Jingxin Pharma is a pharmaceutical company that manufactures and markets traditional Chinese medicine. The company's products includes finished dosage forms, Chinese herbal drugs and APIs. Its finished dosage products comprise simvastatin tablets, lovastatin capsules, fenofibrate capsules, gliclazid tablets, cilnidipine capsules, sertraline hydrochlori...

Friday 10th August 2018

Capricor Therapeutics (CAPR) Q2-2018

On Thursday, August 9, 2018, Capricor Therapeutics released its results for Q2-2018 and held a conference call. We also recently met with CFO AJ Bergmann as well as the Scientific staff at Capricor’s headquarters and laboratories near Cedar-Sinai Hospital.IntroductionCapricor Therapeutics (CAPR) is a small Beverly Hills biopharmaceutical developing innovative treatments to treat heart disease. C...

Alnylam Announces First-Ever FDA Approval of an RNAi Therapeutic, ONPATTRO™ (patisiran) for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults

− First and Only FDA-approved Treatment Available in the United States for this Indication – − ONPATTRO Shown to Improve Polyneuropathy Relative to Placebo, with Reversal of Neuropathy Impairment Compared to Baseline in Majority of Patients – − Improvement in Specified Measures of Quality of Life and Disease Burden Demons...

A1M Pharma’s candidate drug ROSgard™ shows protective effect against acute kidney injury in US study

A1M Pharma AB (publ), 556755-3226 Press release 2018-08-10. A1M Pharma announces that the company's candidate drug ROSgard™ shows a strong protective effect against acute kidney injury (AKI) in a preclinical study conducted in the USA in collaboration with Indiana University. The positive results correlate well with recently reported results from a similar study conducted in Euro...

100 AIDS Advocates to Protest FL Gov. Rick Scott -- Miami Freedom Tower TODAY (Fri., Aug. 10) @ 1:30pm

Governor Rick Scott Denies Healthcare Coverage to Hispanic/Latino Americans and Other Vulnerable Populations Living with HIV/AIDS in the Epicenter of the Nations HIV/AIDS Epidemic. Approximately 100 HIV/AIDS Advocates call out the recent denial of a Medicaid managed healthcare plan that addresses the critical, life-saving medical needs of Hispanic...

MSN Group's affiliate Novadoz Pharma receives marketing nod for generic rosuvastatin, capecitabine & moxifloxacin

Novadoz Pharmaceuticals, the US sales & marketing affiliate of MSN Group (MSN) from Hyderabad, India has received approval to market the company's first products, Rosuvastatin, Capecitabine, and Moxifloxacin tablets.

Thursday 9th August 2018

Corcept Q2-2018 Update: Downward Sales Guidance and Upward Sails into Clinical Results

On Thursday, August 9, 2018, Corcept Therapeutics (CORT) reported

Catabasis Pharmaceuticals Reports Second Quarter 2018 Financial Results and Reviews Business Progress

-- Edasalonexent Phase 3 PolarisDMD Trial in Duchenne Muscular Dystrophy Expected to Initiate in the Second Half of 2018 -- Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2018, and reviewed

Ironshore Pharmaceuticals Announces FDA Approval of JORNAY PMTM (Methylphenidate) Extended-Release Capsules CII for the Treatment of ADHD

JORNAY PM approved for the treatment of ADHD in patients 6 years and older JORNAY PM is the only stimulant medication that is dosed in the evening and has demonstrated improvement in the severity of ADHD symptoms in the early morning and throughout the day The commercial launch of JORNAY PM is planned for the fi...

Therachon Raises $60 Million Mezzanine Financing to Advance Lead Program in Achondroplasia and to Expand Rare Disease Pipeline

- Jørgen Søberg Petersen, M.D., Ph.D., DMSc, MBA and Timothy Anderson to Join Board of Directors - Therachon AG, a clinical-stage biotechnology company focused on rare diseases, today announced it has completed a $60 million mezzanine financing led by Novo Holdings and joined by new investors Cowen Healthcare Investments, Pfizer Ventures and funds ma...

NICE recommends Eli Lilly's psoriatic arthritis drug

Eli Lilly have announced that the monoclonal antibody ixekizumab, has been recommended by NICE for use as a treatment option in England and Wales for adults with active psoriatic arthritis (PsA), after inadequate response to DMARDs (disease modifying antirheumatic drugs). Ixekizumab was granted EU marketing authorisation in January 2018. The efficacy and safety of ixekizumab was determined from th...

Wednesday 8th August 2018

Tricida Announces Second Quarter 2018 Financial Results and Provides Update on Key Initiatives

Completed Positive Pivotal Phase 3 Trial for TRC101 Completed $255.6 Million Initial Public Offering Webcast Today at 5:00 pm ET Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of TRC101, a non-absorbed, orally-dosed polymer designed to treat metabolic acidosis in patients ...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks